Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 12, 2012Therapeutic Advances in Medical OncologyOpen Access

Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMatti AaproUniversità Cattolica del Sacro CuorePCPaul CornesUniversity Hospitals Bristol NHS Foundation TrustDSDiana SunFlorida Atlantic University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Aapro et al. (2012) studied this question.

synapsesocial.com/papers/6a8a57577f5a142c17c1425ehttps://doi.org/10.1177/1758834012444499
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Use of Biosimilar Epoetin to Increase Hemoglobin Levels in Patients with Chemotherapy-Induced Anemia: Real-Life Clinical Experience2012 · 26 citations
  2. 2Update on Erythropoiesis-Stimulating Agents and Clinical Trials in Oncology2009 · 25 citations
  3. 3Biosimilars: current status and future directions2010 · 75 citations
  4. 4The cost of blood transfusion in Western Europe as estimated from six studies2012 · 100 citations
  5. 5Randomized, Multicenter, Controlled Trial Comparing the Efficacy and Safety of Darbepoetin Alfa Administered Every 3 Weeks With or Without Intravenous Iron in Patients With Chemotherapy-Induced Anemia2008 · 196 citations